NIPPON KINZOKU 'Eco-Product' Series - Vol. 2,
NK-301ZF combines high strength with high ductility, enabling both weight reduction of parts and simplification of manufacturing processes. This contributes to improved energy efficiency and reduced environmental impact throughout the customer's entire manufacturing process. Additionally, its enhanced design flexibility allows for optimization of shapes and specifications, leading to improved processing efficiency and yield. These characteristics have led to its adoption in a wide range of applications.
At our company, NK-301ZF is designated as an 'Eco-Product' based on these considerations. We are committed to sustainable manufacturing through the promotion of environmentally friendly materials, with the goal of achieving Net Zero CO₂ emissions by 2050.
This product was developed in accordance with NIPPON KINZOKU's 11th business plan, 'NIPPON KINZOKU 2030', which is focused on the key concept of 'Near Net Performance" -achieving the performance required by end products through material design. Our objective is to further expand its sales in the automotive, electronic components, semiconductors, and related markets.
Features
1. Chemical Composition
The chemical composition is adjusted to meet the JIS standard range.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Chemical-Composition.pdf
2. Mechanical Property
Compared to conventional SUS301, NK-301ZF has greater elongation, helping to prevent cracking during forming. It is also a high-strength material that can achieve a hardness level of HV580 or higher.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Mechanical-Properties.pdf
At equivalent strength levels, it offers higher elongation and superior ductility to conventional SUS301.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Relationship-Between-Hardness-and-Elongation.pdf
3. Fatigue Resistance, Processability
We controlled the inclusions in the steel, which significantly reduced the amount of macroscopic nonmetallic inclusions.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Image-of-Inclusions.pdf
Consequently, we anticipate improved fatigue resistance.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/MIT-test-results.pdf
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Life Sciences BC's 10th Annual Invest in BC Conference Connects Industry Leaders
VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences British Columbia (LSBC) is proud to present the 10th Annual Invest in BC, powered by Lumira Ventures, taking place October 28–29, 2025 at the Vancouver Convention Centre West. Celebrating a decade of impact, Invest in BC has become a cornerstone event for the province's thriving life sciences sector. It brings together investors, entrepreneurs, researchers, and industry leaders for two days of high-impact networking, strategic partnering, and investment exploration. Whether attending to pitch, partner, or learn, participants will find unparalleled opportunities to connect and collaborate. 'Invest in BC is where innovation meets opportunity,' said Wendy Hurlburt, President and CEO of Life Sciences BC. 'This event brings together the full spectrum of our ecosystem—from early-stage ventures to global industry leaders—to spark conversations, build relationships, and accelerate the future of health.' Event Highlights: 30+ companies pitching across Biotech, MedTech, and Digital Health Dedicated partnering sessions for one-on-one meetings Exhibitor booths showcasing cutting-edge industry solutions Panels featuring ecosystem thought leaders Networking to spark meaningful connections Companies Selected to Pitch Include: Arbutus Medical, ARC Medical, AVEE HEALTH, Bold Therapeutics, Careteam Technologies, eSense Health, Evolved Therapeutics, Eyam Health, EyecareX, GuideStar Medical Devices, HTuO Biosciences, Ikomed, ImageCyte Technologies, Integrated Nanotherapeutics, Kapoose Creek Bio, Molecular You, NZ Technologies, Optigo Biotherapeutics, Pramana Pharmaceuticals, Redwood AI, Reverb Therapeutics, Seragene Therapeutics, Sonic Incytes, Sonus Microsystems, Sustained Therapeutics, Total Flow Medical, Variational AI, Vesalius Cardiovascular, ViewsML Technologies, VoxCell BioInnovation, and Zymeworks. "British Columbia's world-leading life sciences and biomanufacturing ecosystem continues to thrive, with B.C. companies making lives better globally," said Ravi Kahlon, Minister of Jobs and Economic Growth. "As uncertainty and anti-science sentiment grow south of our borders, B.C. remains a stable, science-driven jurisdiction committed to life sciences research and commercialization. We're making it easier than ever for companies to do business in the province. I invite investors and entrepreneurs to join the momentum and grow their businesses in B.C." Thank You to Our Confirmed Supporters Invest in BC is made possible by the generous support of these organizations: Event Details: Dates Location: Vancouver Convention Centre West Secure Your Spot: Early registration available until September 26. For more information or to register, visit:
Business Wire
26 minutes ago
- Business Wire
Genesco to Report Second Quarter Fiscal 2026 Financial
NASHVILLE, Tenn.--(BUSINESS WIRE)--Genesco Inc. (NYSE: GCO) today announced that the Company will report financial results for the second quarter fiscal 2026 on August 28, 2025, before the market opens, and hold its quarterly earnings conference call at 7:30 a.m. (Central time) the same day. A live audio webcast of the conference call will be available at An audio archive of the call will be available for up to one year at In addition, a summary of the second quarter fiscal 2026 results will be available on the Genesco website on August 28, 2025 at About Genesco Inc. Genesco Inc. (NYSE: GCO) is a footwear focused company with distinctively positioned retail and lifestyle brands and proven omnichannel capabilities offering customers the footwear they desire in engaging shopping environments, including more than 1,250 retail stores and branded e-commerce websites. Its Journeys, Little Burgundy and schuh brands serve teens, kids and young adults with on-trend fashion footwear inspired by youth culture in the U.S., Canada and the U.K. Johnston & Murphy serves the successful, affluent men and women with premium footwear, apparel and accessories in the U.S. and Canada, and Genesco Brands Group sells branded lifestyle footwear to leading retailers under licensed brands including Wrangler, Dockers, Starter and PONY. Founded in 1924, Genesco is based in Nashville, Tennessee. For more information on Genesco and its operating divisions, please visit
Business Wire
26 minutes ago
- Business Wire
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit Our filings with the Securities and Exchange Commission are available online at or on request from the company.
